June 7 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX)
VRX.TO executives spoke on a conference call with analysts:
* Valeant says it has repaid $730M debt in 2016; payments
scheduled to pay further $273M
* Company is re-recruiting employees, attracting new talent
* Company looking to make non-core asset sales, deal with
pricing issues
* Valeant says second quarter performance will be better
than first quarter
Further company coverage: VRX.TO